Zai Lab (09688) announced that its partner and study sponsor Amgen disclosed during its Q3 2025 earnings call on November 4, 2025, the discontinuation of the Phase 1b/3 FORTITUDE-102 clinical trial evaluating bemarituzumab combined with chemotherapy and nivolumab as first-line gastric cancer treatment. The decision followed an interim analysis by the Data Monitoring Committee indicating insufficient efficacy. For more Hong Kong stock market updates, visit the designated financial portal (search "Zhitong Caijing"). To join the Hong Kong stock investment community, contact the platform's customer service.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.